MedTrace Logo

Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

NCT05175768 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-09-23

No results posted yet for this study

Summary

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated with COVID-19 Infection

Conditions

  • COVID-19 Infection

Interventions

OTHER

Nicotinamide Mononucleotide

Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

OTHER

Nicotinamide Mononucleotide with L-Leucine

Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

OTHER

Placebo

Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

Sponsors & Collaborators

  • LGD

    collaborator INDUSTRY

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-27
Primary Completion
2022-07-16
Completion
2022-07-16

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05175768 on ClinicalTrials.gov